Indeed, patients with IgLON5 antibodies typically develop a sleep disorder along with bulbar symptoms, parkinsonism, gait abnormalities, oculomotor disturbances, and sometimes cognitive decline, mimicking a PSP clinical presentation (173, 174). Here, IGLON5 is linked to Parkinsonism.